Oppenheimer raised the firm’s price target on Alnylam (ALNY) to $500 from $490 and keeps an Outperform rating on the shares. The firm notes Amvuttra global revenue of $685M came just shy of its $690M but well ahead of the Street’s $622M, and Alnylam raised full-year TTR franchise guidance by $275M at midpoint.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target raised to $489 from $449 at Piper Sandler
- Alnylam price target raised to $527 from $460 at Barclays
- Alnylam price target raised to $475 from $400 at Chardan
- Alnylam Pharmaceuticals Reports Strong Q3 2025 Growth
- Alnylam Pharma’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating